PGNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Progyny Inc (PGNY) is not a strong buy for a beginner investor with a long-term horizon at this time. While the company's financials show growth and analysts maintain some positive sentiment, the technical indicators, insider selling, and lack of strong trading signals suggest caution. Additionally, the stock is expected to decline in the short term, making it less appealing for immediate investment.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 53.554, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 18.356), suggesting limited upside in the short term.
Analysts highlight stable business trends and healthy member engagement. The company maintains a leading position in its industry.
Insiders have significantly increased selling activity (601.40% in the last month). Analysts have lowered price targets recently due to uncertain outlooks and concerns about employer demand trends. A derivative lawsuit against the board of directors may create additional uncertainty. Technical indicators suggest bearish trends, and the stock is expected to decline in the short term.
In Q4 2025, Progyny achieved revenue of $318.4M (up 6.69% YoY), net income of $12.49M (up 18.54% YoY), EPS of $0.14 (up 27.27% YoY), and gross margin of 24.15% (up 13.59% YoY). These results indicate solid growth but are overshadowed by broader market concerns.
Analysts have mixed views. While some maintain Buy ratings with price targets in the $28-$30 range, others have downgraded targets to $19-$26, citing cautious outlooks and uncertain demand trends. The sentiment is neutral to slightly positive overall.
